Cambrex logo

CBM - Cambrex News Story

$59.99 0.0  0.0%

Last Trade - 03/12/19

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £485.7m
Position in Universe th / 6400

Cambrex to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019

Fri 8th February, 2019 8:46pm
Cambrex to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019

EAST RUTHERFORD, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that fourth quarter and full year 2018 financial results will be released on Wednesday, February 13, 2019 before the market opens.

The Company will host a conference call to discuss the financial results.

 Fourth Quarter 2018 Earnings Conference Call
When:Wednesday, February 13, 2019 at 8:30 a.m. Eastern Time
Dial-in: 1-877-260-1479 for U.S.
 1-334-323-0522 for International 
 Passcode:  2955208
Dial-in Replay:1-888-203-1112 for U.S.
 1-719-457-0820 for International
 Passcode:  2955208
 Available through Wednesday, February 20, 2019

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit

Contact: Stephanie LaFiura 
 Investor Relations Associate
 Tel: 201-804-3037       

© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.